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Aim. The prevalence of cardiovascular autonomic neuropathy (CAN) in diabetes mellitus is well documented. However, the rate
and predictors of both the development and progression of CAN have been less studied. Hereby, we assessed the rate and the
major risk factors for CAN initiation and progression in a cohort of type 1 diabetic patients followed over a three-year period.
Methods. 175 type 1 diabetic patients (mean age: 50± 11 years; female/male: 76/99) with positive bedside screening for CAN
were included and underwent 2 standardized autonomic testings using 4 standardized tests (deep breathing, Valsalva maneuver,
30/15 ratio, and changes in blood pressure during standing), separated by 3± 1 years. CAN staging was achieved according to
the Toronto Consensus Panel on Diabetic Autonomic Neuropathy into 4 categories: absent, possible, conﬁrmed, or severe CAN.
Results. Out of the 175 patients included, 31.4% were free of CAN, 34.2% had possible CAN, 24.6% had conﬁrmed CAN, and
9.7% exhibited severe CAN at the ﬁrst assessment. Among the 103 patients with nonsevere CAN at inclusion, forty-one (39.8%)
had an increase of at least one category when reassessed and 62 (60.2%) remained stable. A bivariate analysis indicated that only
BMI and exposure to selective serotonin reuptake inhibitors (SSRIs) were signiﬁcantly diﬀerent in both groups. A multivariate
analysis indicated that lower BMI (OR: 0.15, CI 95%: 0.05–0.48, p = 0 003) and SSRI exposure (OR: 4.18, CI 95%: 1.03–16.97,
p = 0 04) were the sole predictors of CAN deterioration. In the 55 patients negative for CAN at the ﬁrst laboratory
assessment, 12 became positive at the second assessment. Conclusion. No clear predictive factor for CAN onset was identiﬁed.
However, once present, CAN progression was related to low BMI and SSRI exposure.
1. Introduction
Cardiovascular autonomic neuropathy (CAN) is a com-
mon but often neglected diabetes mellitus complication.
Based on the CAN Subcommittee of the Toronto
Consensus Panel on Diabetic Neuropathy [1], CAN is
deﬁned as the impairment of cardiovascular autonomic
control in patients with established diabetes mellitus fol-
lowing the exclusion of other causes. It is generally
believed that CAN incidence is related to age, duration
of diabetes, poor glycemic control, and microvascular
disease [2–5]. Although unpredictable, CAN progression
results in a signiﬁcant cardiovascular morbidity and
mortality [6].
A better understanding of predictive risk factors for
CAN incidence and progression is crucial for the develop-
ment of new strategies for follow-up as well as of novel
therapeutic targets.
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The purpose of the present study was to assess major risk
factors of CAN onset and progression and to describe the time
line changes in cardiac autonomic dysfunction in a cohort of
type 1 diabetic patients over a mean period of 3 years.
2. Patients and Methods
2.1. Selection of Patients. 175 consecutive type 1 diabetic
patients attending the Department of Diabetes and Metabo-
lism of Toulouse University Hospital between July 2003
and June 2010 and who had a positive bedside screening for
CAN were included. Patients on beta-blocker treatment at
selection were not included. The screening for CAN included
3 cardiovascular reﬂex tests described by Ewing and Clarke
[7]: the heart rate (HR) response to deep breathing, which
assesses beat-to-beat HR variation (R-R variation) during
paced deep breathing [expiration-to-inspiration ratio (E:I)];
the initial HR response to standing expressed as the 30 : 15
ratio (ratio of the longest R-R interval (around the 30th beat)
to the shortest R-R interval (around the 15th beat)) elicited
by a change from the horizontal to vertical position; and
the blood pressure (BP) response to standing. A single abnor-
mal result suﬃces to suspect the diagnosis of possible CAN.
The study was performed according to the French law for
clinical research.
2.2. Laboratory Autonomic Testing. All patients with a posi-
tive screening for CAN underwent more elaborated tests as
previously described [8]. The autonomic laboratory evalua-
tion was based on continuous digital BP (photoplethysmo-
graphy, Nexﬁn) and computerized ECG recordings during
the following tests: paced deep breathing test (6 cycles/
min), Valsalva maneuver (40mmHg, 15 sec) performed in
supine position, a 5min stand test, and a 3min isometric
exercise (hand grip, 30% of maximal force) performed in
seated position. The Ewing score (ES) was based on the fol-
lowing parameters: HR changes with deep breathing, 30/15
ratio, Valsalva ratio (HR max during maneuver :HR min
during recovery), BP response to active standing, and dia-
stolic BP increase to hand grip. The response to each test
was considered normal (0), borderline (0.5), or abnormal
(1) according to the laboratory normal values for age. Ortho-
static hypotension (OH) was deﬁned as a reduction in sys-
tolic BP of at least 20mmHg and/or diastolic BP of at least
10mmHg within 3 minutes of standing. The Ewing score
(ES) ranging from 0 (normal) to 5 (severe autonomic failure)
represents the sum of the responses to the diﬀerent tests.
Further assessment was performed using the Toronto
Consensus classiﬁcation based on previous tests except iso-
metric hand grip: absence of CAN (no abnormal response,
score 0), possible (one abnormal cardiovagal test, score 1),
conﬁrmed (at least 2 abnormal cardiovagal tests, score 2),
and severe (1 abnormal cardiovagal test plus orthostatic
hypotension, score 3).
2.3. Selection of CAN Potential Predictors.At the time of CAN
screening, the following clinical characteristics of the patients
were recorded: age, weight, body mass index (BMI), HbA1c
level, diabetes duration, insulin treatment (subcutaneous
insulin infusion or multiple daily injection), and diabetes-
related complications. Diabetic nephropathy was assessed
using the estimated glomerular ﬁltration rate (eGFR), which
was calculated using the MDRD equation and the urinary
albumin/creatinine ratio (ACR) of a single early morning
urine. Stage 1 nephropathy was considered for ACR between
30 and 299mg/g, and stage 2 nephropathy was considered for
ACR ≥ 300 mg/g and/or an eGFR< 60ml·min−1 per 1.73m2.
Retinopathy stages included mild nonproliferative (NPR)
(stage 1), moderate NPR (stage 2), and severe NPR or prolif-
erative retinopathy and scatter laser treatment (stage 3). Knee
and ankle reﬂexes, distal vibration perception, and pinprick
tests were performed. Clinical distal peripheral neuropathy
was diagnosed on at least one abnormal test. Associated
cardiovascular risk factors such as arterial hypertension,
hypercholesterolemia, and smoking were recorded. Silent
myocardial ischemia was assessed using an exercise stress test
or stress thallium myocardial perfusion imaging.
2.4. Statistical Analysis. Analyses were performed using
STATA Version 10. Numerical variables with normal distri-
bution are expressed as means ± SD and reported as median
(interquartile range). Bivariate comparisons were performed
by a chi-square test for categorical variables or by t-test for
numerical variables (with adjustments for unequal variances
when needed). A multivariate analysis was performed by
logistic regression. All variables with bivariate p value < 0 10
were included. Numerical variables were categorized in ter-
tiles for the exploration of the nonlinear relationship with
the dependent variable. If present, the categorical variable
was included in the multivariate model instead of the original
numerical one. Multicolinearity was explored by correlation
coeﬃcients. Only participants with two complete and analyz-
able autonomic testings during the period of the study were
included in the statistical analysis.
3. Results
3.1. Characteristics of the Studied Population. One hun-
dred seventy-ﬁve (175) consecutive type 1 diabetic patients,
who had a positive bedside screening for CAN (mean age:
50± 11 years, M/F: 1.30), were included in the study. One
hundred ﬁfty-eight out of 175 patients underwent a second
complete and analyzable autonomic testing after a mean time
interval of 3.0± 1.1 years.
The clinical and biochemical characteristics of the study
population are depicted in Table 1. Mean BMI, duration of
diabetes, and HbA1c level were 24.4± 3.0 kg/m2, 26± 11
years, and 7.9± 1.2%, respectively. Forty-two percent (42%)
of patients were on subcutaneous insulin infusion, 12% were
on intraperitoneal insulin infusion, and 46% received multi-
ple daily injections.
Prevalence rates of arterial hypertension, hypercholes-
terolemia, and current smoking were 40.0%, 33.1%, and
28.6%, respectively. Concerning diabetes-related complica-
tions, 30.8% had diabetic nephropathy, of which 11% were
at stage 2 nephropathy (ACR≥ 300mg/g and or an
eGFR< 60ml·min−1 per 1.73m2). The prevalence of reti-
nopathy at any stage was around 67.4%, of whom 38%
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were at stage 3 retinopathy. Peripheral neuropathy was
found in 44%. 75% of the patients underwent screening
for silent ischemic cardiac disease at the time of the ﬁrst
visit with only 3 positive screenings. The prevalence of
neurovegetative disorders including gastrointestinal symp-
toms, bladder dysfunction, cardiovascular symptoms, and
erectile dysfunction was found in 26.9%, 28.6%, 36.0%,
and 29.1%, respectively.
According to Spallone et al. [1], ﬁfty-ﬁve patients (31.4%)
out of the 175 included did not have CAN at laboratory
assessment. Sixty patients (34.2%) had possible CAN, 43
(24.6%) had a conﬁrmed CAN, and 17 (9.7%) had severe
CAN. An abnormal HR response to deep breathing was
found in 61.2%, abnormal HR response to standing in
29.7%, abnormal Valsalva ratio or abnormal response to sus-
tained hand grip in 12%, and, ﬁnally, orthostatic hypotension
in 10.3%.
3.2. Risk Factors for CAN Progression over a Three-Year
Period. One hundred and three (103) patients out of 158,
with at least possible or more severe CAN at ﬁrst laboratory
assessment, had a second complete and analyzable testing.
In sixty-two patients (51.7%), CAN severity remained stable
or improved during the study period whereas worsening
(change from possible to conﬁrmed or from conﬁrmed to
severe CAN) was found in 41 patients (34.2%). The tests
which became more frequently abnormal were the HR
response to standing in 21% and the blood pressure response
to sustained hand grip and Valsalva ratio in 14% and 15%,
respectively. The blood pressure response to standing
became abnormal in only 8% of the cases.
The characteristics of the two groups are shown in
Table 2. A bivariate analysis indicates that age; gender; diabe-
tes duration; cardiovascular-associated risk factors; morbid-
ities including peripheral neuropathy, retinopathy, and
nephropathy; and treatment modalities were not signiﬁcantly
diﬀerent between the 2 groups. However, the mean BMI
value was signiﬁcantly lower (p = 0 047), and the exposure
to selective serotonin reuptake inhibitors (SSRIs) was signif-
icantly higher (0.04) in patients from group II. In a multivar-
iate analysis, both BMI and SSRI exposure were found to be
independently related to CAN deterioration (Table 2).
3.3. Risk Factors for CAN Initiation over a Three-Year Period.
Fifty-ﬁve (55) patients had no CAN at inclusion. Among
them, 43 (78.2%) remained free from CAN at the end of
the study, and 12 (21.8%) became positive on the second
autonomic testing.
The clinical and biochemical characteristics of patients
with persistent negative CAN and those who were positive
for CAN upon the second reassessment were not statistically
diﬀerent (Table 3). A trend for higher exposure to diuretics in
the group developing CAN (n = 2 patients) versus the group
remaining free from CAN (n = 1 patient) was noticed but did
not reach the level of signiﬁcance (p = 0 053), and the very
limited number of patients makes this ﬁnding nonrelevant.
4. Discussion
Previous studies provided information about cardiovascular
autonomic neuropathy (CAN) prevalence in subjects with
type 1 diabetes, but few of them raised the issue of the rate
and predictors of CAN progression. The main results of the
present study are that no clear risk factor was related to
CAN onset and that factors associated with CAN progression
from the mild stage are low BMI and SSRI exposure.
The interpretation of our results has to be made keeping
in mind that the population included in this study is not rep-
resentative of the global type 1 diabetic population. In fact,
according to the strategy in our institution, and as recom-
mended by French guidelines at the time of the study [9],
only patients with at least one abnormal response to 3
bedside-performed screening tests were addressed for com-
plete autonomic laboratory testing. Moreover, patients
receiving beta-blockers, which could modify results of auto-
nomic tests, were discarded, thus explaining the low rate of
silent myocardial ischemia. Despite these potential biases,
the observed frequency of CAN severity in this survey is
coherent with previously published results [8, 10]. The selec-
tion strategy also explains that only a relatively reduced
number of patients were free of cardiovascular autonomic
neuropathy at the ﬁrst assessment, thus making the evalua-
tion of CAN incidence not realistic from our results. How-
ever, we observed that a reduced proportion of initially
normal patients (21.8%) developed autonomic neuropathy
within a 3-year period.
Our criterion for CAN progression was an increase of at
least one point in the Spallone scoring. Indeed, very few stud-
ies investigated the progression rate of autonomic dysfunc-
tion in diabetes mellitus, and most of them concentrated on
Table 1: Baseline characteristics of the cohort of type 1 diabetic
patients.
N = 175
Demographic characteristics
Age (years) 50± 11
Women/men 76/99
Diabetes duration (years) 26± 11
HbA1c (%) 7.9± 1.2
BMI (kg/m2) 24.4± 3
Complications and comorbidities
Nephropathy 54 (31%)
Retinopathy 118 (67%)
Peripheral neuropathy 77 (44%)
Hypertension 70 (40%)
Dyslipidemia 58 (33%)
Tobacco smoking 50 (29%)
Silent myocardial ischemia 3 (2%)
Neurovegetative symptoms
Cardiovascular 63 (36%)
Digestive 47 (27%)
Erectile dysfunction 51 (52%)
Bladder dysfunction 50 (29%)
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Table 2: Baseline clinical and biochemical characteristics of type 1 diabetic patients with mild CAN who remained stable (group I) or had
CAN worsening (group II) for over a mean period of 3 years.
Group I (n = 62) Group II (n = 41) p value Logistic regression OR (95% CI)
Age (years) 50.69± 1.36 47.63± 1.57 0.15
Males 39 (63%) 22 (54%) 0.35
Diabetes duration (years) 26.32± 1.45 26.12± 1.62 0.92
≤20 21 (34%) 13 (32%) 0.8
21–30 22 (35%) 13 (32%)
>30 19 (31%) 15 (37%)
BMI (kg/m2) 25.07± 0.38 23.58± 0.5 0.018
≤22.94 16 (26%) 20 (49%) 0.003 1
22.94–25.68 17 (27%) 15 (37%) 0.73 (0.28–1.95)
>25.68 29 (47%) 6 (15%) 0.15 (0.05–0.48)
HbA1c (%) 7.76± 0.13 8.08± 0.2 0.16
≤7.4 23 (37%) 11 (27%) 0.25
7.5–8.2 24 (39%) 14 (34%)
>8.2 15 (24%) 16 (39%)
DPN 27 (44%) 18 (44%) 0.97
Nephropathy 0.72
0 44 (71%) 26 (63%)
1 11 (18%) 9 (22%)
2 7 (11%) 6 (15%)
Retinopathy 0.18
0 22 (35%) 7 (17%)
1 8 (13%) 8 (20%)
2 10 (16%) 6 (15%)
3 22 (35%) 20 (49%)
Microalbuminuria (mg/24 h) 41± 12.32 163.16± 69.92 0.09
≤7.0 23 (37%) 11 (27%) 0.44
7.1–14.6 20 (32%) 13 (32%)
>14.7 19 (31%) 17 (41%)
Clearance (ml/min) 80.46± 2.02 79.26± 3.71 0.75
≤73.87 20 (32%) 18 (44%) 0.37
73.87–88.49 26 (42%) 12 (29%)
>88.49 16 (26%) 11 (27%)
Hypertension 25 (40%) 13 (32%) 0.37
Tobacco smoking 18 (29%) 12 (30%) 0.91
Dyslipidemia 17 (27%) 16 (39%) 0.21
CSII 0.39
0 28 (45%) 23 (56%)
1 27 (44%) 16 (39%)
2 7 (11%) 2 (5%)
HMG-CoA inhibitors 16 (26%) 14 (34%) 0.36
CEI/AT1 antagonists 26 (42%) 16 (39%) 0.76
Antiaggregants 7 (11%) 5 (12%) 0.89
Diuretics 5 (8%) 6 (15%) 0.27
Calcium inhibitors 4 (6%) 3 (7%) 0.86
SSRIs 4 (6%) 8 (20%) 0.04 4.18 (1.03–16.97)
Shown are means ± standard error of the mean. DPN: distal peripheral neuropathy; CV: cardiovascular; CSII: continuous subcutaneous and intraperitoneal
insulin infusion; NC: not calculated. Data were analyzed according to Statistical Analysis.
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Table 3: Baseline clinical and biochemical characteristics of type 1 diabetic patients without CAN at inclusion who remained stable (no CAN)
or developed autonomic dysfunction (CAN) for over a mean period of 3 years.
No CAN (n = 43) CAN (n = 12) p value No CAN (n = 43) and
not No CAN (n = 43)
Age (years) 52.12± 1.56 56.33± 3.56 0.23
Males 27 (63%) 6 (50%) 0.42
Diabetes duration (years) 25.47± 1.83 22.17± 2.66 0.38
≤20 19 (44%) 6 (50%) 0.09
21–30 8 (19%) 5 (42%)
>30 16 (37%) 1 (8%)
BMI (kg/m2) 23.74± 0.67 24.27± 0.71 0.69
≤22.94 12 (28%) 4 (33%) 0.87
22.94–25.68 17 (40%) 5 (42%)
>25.68 14 (33%) 3 (25%)
HbA1c (%) 8.07± 0.18 7.57± 0.37 0.21
≤7.4 14 (33%) 6 (50%) 0.53
7.5–8.2 14 (33%) 3 (25%)
>8.2 15 (35%) 3 (25%)
DPN 16 (37%) 5 (42%) 0.79
Nephropathy 0.13
0 32 (74%) 11 (92%)
1 10 (23%) 0 (0%)
2 1 (2%) 1 (8%)
Retinopathy 0.89
0 19 (44%) 6 (50%)
1 6 (14%) 2 (17%)
2 6 (14%) 2 (17%)
3 12 (28%) 2 (17%)
Microalbuminuria (mg/24 h) 44.71± 27.74 7.76± 1.32 0.48
≤7.0 17 (40%) 8 (67%) 0.25
7.1–14.6 12 (28%) 2 (17%)
>14.7 14 (33%) 2 (17%)
Clearance (ml/min) 85.31± 2.32 81.1± 4.68 0.4
≤73.87 9 (21%) 5 (42%) 0.34
73.87–88.49 15 (35%) 3 (25%)
>88.49 19 (44%) 4 (33%)
Hypertension 17 (40%) 6 (50%) 0.48
Tobacco smoking 10 (23%) 4 (33%) 0.5
Dyslipidemia 16 (37%) 3 (25%) 0.43
CSII 0.6
0 16 (37%) 6 (50%)
1 19 (44%) 5 (42%)
2 8 (19%) 1 (8%)
HMG-CoA inhibitors 9 (21%) 1 (8%) 0.31
CEI/AT1 antagonists 19 (44%) 7 (58%) 0.38
Antiaggregants 7 (16%) 0 (0%) 0.13
Diuretics 1 (2%) 2 (17%) 0.053
Calcium inhibitors 4 (9%) 0 (0%) 0.27
SSRIs 4 (9%) 0 (0%) 0.27
DPN: distal peripheral neuropathy; CV: cardiovascular; CSII: continuous subcutaneous and intraperitoneal insulin infusion; NC: not calculated. Data were
analyzed according to Statistical Analysis.
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the prevalence of CAN. In these studies, the usual minimal
score to diagnose CAN is 2 abnormal responses to cardiova-
gal tests to discard the false positive assessment of CAN [1].
In fact, the response to the tests composing the autonomic
battery we used is highly dependent on the quality of patient
performance. The choice of a one-point increase in auto-
nomic score to deﬁne CAN progression was made in order
to detect minimal changes accounting for progression. How-
ever, special attention was paid to the conditions in which
autonomic testing was performed. In fact, all testings were
performed at entry and at study end in the same laboratory
by the same persons, and exactly the same devices were used
in order to reduce the variability of the measured parameters.
However, we cannot exclude that, despite these cautions, our
experimental design could have led to some overestimation
of the progression of CAN.
Other confusion biases potentially accounting for
changes in the autonomic score at the second testing could
result from changes in diabetes treatment. However, our data
showed that cardiac autonomic neuropathy in long-standing
type 1 diabetic patients is associated with the progression of
autonomic dysfunction. During the DCCT/EDIC study,
diabetes duration and degree of glycemic control were
the dominant determinants of the risk progression of micro-
vascular complications in type 1 diabetic patients [3]. How-
ever, CAN prevalence increased in both intensive and
conventionally treated groups even if it was signiﬁcantly
lower in the former intensive group than in the former con-
ventional group (28.9% versus 35.2%; p = 0 018) [3], thus
suggesting that hyperglycemia is not the sole mechanism
involved in CAN progression.
Regarding the progression of CAN, the present study
demonstrates that 39.8% of the patients with mild autonomic
dysfunction progress to a more advanced stage over a three-
year period and that progression is related to low BMI and
SSRI exposure but not to HbA1c level, disease duration, ret-
inopathy, peripheral neuropathy, or nephropathy. Despite
previous studies postulating that the progression of CAN is
slow [11, 12] and linked to diabetes duration, blood glucose
control, and microangiopathic complications [13–15], the
nature of CAN progression predictors remains controversial.
The progression of CAN has been shown to be positively cor-
related with low BMI, but, in the contrary, several studies
reported obesity as a positive predictive factor for CAN pro-
gression in nondiabetic and type 1 and 2 diabetic patients [2].
Since most evidences indicate that low BMI is a marker of
uncontrolled diabetes and thus a risk factor for CAN deteri-
oration, our results have to be taken with caution and will
need conﬁrmation in speciﬁc future studies. In our study,
the HbA1c level was not statistically diﬀerent between
patients that deteriorate their CAN and those who did not.
This might be explained by the fact that the HbA1c level
was measured at a point time related to the ﬁrst CAN screen-
ing and does only show the blood glucose control over the
last three-month period. Another possibility is that HbA1c
is not a good indicator of blood glucose variability promoting
hypoglycemic stress that was associated in a recent study
with reduced heart rate variability independent of glycemic
control as assessed by HbA1c [16]. Thus, it could be
suggested that glucose variability rather than glucose levels
contributes to cardiovascular autonomic dysfunction among
adults with type 1 diabetes.
Our ﬁndings are surprising since diabetic CAN has been
repeatedly reported to associate with nephropathy and since
autonomic neuropathy is encountered in approximatively
60% of the patients with chronic kidney disease. The rela-
tionship between CAN and nephropathy in diabetes is rather
complex and unclear. In fact, on one hand, CAN may be an
aggravating factor of nephropathy [14]. A faster rate over 1
year of the progression of renal dysfunction was suggested
in type 1 diabetic patients with autonomic dysfunction [17].
Nephropathy was found to be an independent risk factor
for CAN prevalence [18]. On the other hand, autonomic
neuropathy was not considered to be a progression pro-
moter in diabetic nephropathy in a prospective observational
follow-up study including 388 type 1 diabetic patients with
(n = 197) and without (n = 191) diabetic nephropathy
followed for 10.1 years [19]; in this study, there was no
relationship between CAN and a faster decline in GFR.
Finally, several authors have hypothesized that CAN is indi-
rectly involved in the pathogenesis of diabetic nephropathy,
via hemodynamic changes such as lack of nocturnal BP dip-
ping (causing increased intraglomerular pressure resulting in
albuminuria) and diurnal postural falls in BP (resulting in
lower intraglomerular pressure) and endothelial dysfunction
[19]. Others suggested that CAN is a strong predictor of
nephropathy and participates in the progression of chronic
kidney disease through deﬁcient erythropoietin production
and anemia [20–22].
We found that serotonin reuptake inhibitor exposure was
higher in patients with CAN progression. This ﬁnding ﬁrst
suggests an indirect link between SSRIs and CAN worsening.
In fact, even if SSRIs are not ﬁrst-line recommended drugs
for diabetic neuropathic pain, antidepressants are often used
in diabetes, and, globally, an association between their use
and CAN worsening could be related to a higher frequency
of depressive symptoms in worsening patients. In fact, our
data indicate that there is a signiﬁcant diﬀerence (p = 0 04;
OR: 4.18 [1.03–16.97]) in the frequency of SSRI use in
patients with neuropathy in both patients remaining stable
(6%) and worsening ones (20%). Secondly, it could suggest
that SSRI drugs worsen diabetes equilibrium, thus favoring
CAN progression. However, on the one hand, no diﬀerences
in diabetes characteristics, including HbA1c, were found
between stable and worsening patients, and, on the other
hand, data from literature about eﬀects of SSRIs on diabetes
remain controversial. In young patients with type 1 diabetes,
SSRIs have been found to be associated with negative clinical
outcomes, an eﬀect ascribed to the impact of comorbid
depression on the quality of diabetes treatment [23]. By
contrast, other studies have reported lower insulin require-
ment for the control of type 1 diabetes in patients receiv-
ing SSRIs [24]. Finally, another hypothesis could be the
negative impact of SSRIs on autonomic nervous system
activity. Data from the literature converge on neutral
eﬀects of SSRIs on autonomic function when compared
to older tricyclic antidepressants [25]. SSRIs have also
been proposed for the management of vasovagal syncope
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[26] or orthostatic hypotension in neurodegenerative dis-
orders such as Parkinson’s disease [27], but there are no
data in orthostatic hypotension in diabetes mellitus.
5. Conclusion
Few studies raised the question about the initiation and pro-
gression of CAN in type 1 diabetic patients, which makes this
paper original. The main ﬁndings are that no clear factors
seem to be associated with CAN onset while its worsening
is correlated with low BMI and SSRI exposure but not with
classical clinical or biological disease parameters. Despite
some limitations, resulting from the study design and the
number of patients in subgroups which limit conclusions
about any causal relation between CAN progression and
other microvascular and macrovascular diabetes-related
complications, these data suggest that mechanisms underly-
ing the onset andworsening of autonomic dysfunction in type
1 diabetes are diﬀerent. However, larger prospective studies
with longer follow-up are needed to conﬁrm these results.
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